These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 30659749)

  • 21. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.
    Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Preidl R; Neukam FW; Ries J
    Oncotarget; 2017 Dec; 8(68):112584-112597. PubMed ID: 29348848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
    Jiang C; Yuan F; Wang J; Wu L
    Immunobiology; 2017 Apr; 222(4):651-657. PubMed ID: 28017495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
    Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
    Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
    Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
    Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
    Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
    Pittet CL; Newcombe J; Prat A; Arbour N
    J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
    Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
    Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lectin-like Transcript-1 (LLT1) Expression in Oral Squamous Cell Carcinomas: Prognostic Significance and Relationship with the Tumor Immune Microenvironment.
    de Vicente JC; Lequerica-Fernández P; Rodrigo JP; Rodríguez-Santamarta T; Blanco-Lorenzo V; Prieto-Fernández L; Corte-Torres D; Vallina A; Domínguez-Iglesias F; Álvarez-Teijeiro S; García-Pedrero JM
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
    Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
    Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
    Lin YM; Sung WW; Hsieh MJ; Tsai SC; Lai HW; Yang SM; Shen KH; Chen MK; Lee H; Yeh KT; Chen CJ
    PLoS One; 2015; 10(11):e0142656. PubMed ID: 26562534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.